Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

An­ti­body-drug con­ju­gates, one of the creams of the crop in 2023 bio­phar­ma deal­mak­ing, are rid­ing in­to 2024 on a strong note as Roche pays $50 mil­lion up­front to col­lab­o­rate with a biotech in Chi­na, where many of the ADC deals have been made re­cent­ly.

The Swiss Big Phar­ma is pair­ing up with Suzhou-based MediLink Ther­a­peu­tics, which teamed with BioN­Tech last fall for $70 mil­lion up­front and with Zai Lab last April for an undis­closed amount.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.